secwatch / observer
8-K filed May 12, 2023, 7:59 PM ET ticker INBS CIK 0001725430
other material confidence high sentiment neutral materiality 0.75

Stockholders approve conversion of preferred shares; outstanding common to increase ~44% to 2.3M

INTELLIGENT BIO SOLUTIONS INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve the full conversion of Series C Convertible Preferred Stock and the issuance of shares of Common Stock in connection with such conversion.

Outcome
passed
Exact text from the filing
FOR AGAINST ABSTAIN 530,145 7,392 71,927
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve an increase in the number of shares of Common Stock authorized for issuance under the 2019 Plan by 50,000 shares.

Proposal
equity plan
Outcome
passed
Exact text from the filing
FOR AGAINST ABSTAIN 584,036 25,164 264
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve the full conversion of Series D Convertible Preferred Stock and the issuance of shares of Common Stock in connection with such conversion.

Outcome
passed
Exact text from the filing
FOR AGAINST ABSTAIN 585,379 23,657 428
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. shareholders approved To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies.

Outcome
passed
Exact text from the filing
FOR AGAINST ABSTAIN 583,313 25,538 613
View on SEC.gov

Browse all shareholder votes →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR
accession 0001493152-23-016739
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.